In summary, this study found that cervical prescription mainly uses TGFβ1, PPP6C, HIF1A, IL1B, and other gene targets through network pharmacology and regulates cancer pathways, FoxO signaling pathway, IL-17, and other signaling pathways to regulate immunity and improve cervical cell pathology in patients with cervical cancer, thereby exerting therapeutic effects of cervical cancer. This evidence concerns the gene IL1B and cervical carcinoma.